Table 2.
ODs and ED for (+)-[18F]flubatine based on piglet data
| Target organ | OD | SD | ED contribution | SD |
|---|---|---|---|---|
| (mSv/MBq) | (mSv/MBq) | |||
| Adrenals | 1.11E−02 | 7.64E−04 | 9.57E−05 | 6.57E−06 |
| Brain | 3.23E−02 | 3.24E−03 | 3.23E−04 | 3.24E−05 |
| Breasts | 6.21E−03 | 5.15E−04 | 7.45E−04 | 6.18E−05 |
| Gallbladder wall | 1.81E−02 | 1.18E−03 | 1.56E−04 | 1.02E−05 |
| LLI wall | 1.15E−02 | 4.04E−04 | 6.88E−04 | 2.42E−05 |
| Small intestine | 1.48E−02 | 1.00E−03 | 1.27E−04 | 8.61E−06 |
| Stomach wall | 1.10E−02 | 6.51E−04 | 1.32E−03 | 7.81E−05 |
| ULI wall | 1.52E−02 | 1.15E−03 | 9.12E−04 | 6.92E−05 |
| Heart wall | 1.42E−02 | 2.15E−03 | 1.22E−04 | 1.85E−05 |
| Kidneys | 4.51E−02 | 6.50E−03 | 3.88E−04 | 5.59E−05 |
| Liver | 2.69E−02 | 4.78E−03 | 1.07E−03 | 1.91E−04 |
| Lungs | 1.39E02 | 2.00E−04 | 1.67E−03 | 2.40E−05 |
| Muscle | 7.77E−03 | 4.03E−04 | 6.68E−05 | 3.46E−06 |
| Ovaries | 1.07E−02 | 2.08E−04 | 8.53E−04 | 1.67E−05 |
| Pancreas | 2.24E−02 | 1.78E−03 | 1.93E−04 | 1.53E−05 |
| Red marrow | 1.15E−02 | 1.07E−03 | 1.38E−03 | 1.28E−04 |
| Osteogenic cells | 1.35E−02 | 1.21E−03 | 1.35E−04 | 1.21E−05 |
| Skin | 5.87E−03 | 4.13E−04 | 5.87E−05 | 4.13E−06 |
| Spleen | 2.01E−02 | 9.07E−04 | 1.73E−04 | 7.80E−06 |
| Testes | 7.70E−03 | 6.51E−05 | – | – |
| Thymus | 1.82E−02 | 3.27E−03 | 1.56E−04 | 2.81E−05 |
| Thyroid | 1.77E−02 | 8.90E−03 | 7.07E−04 | 3.56E−04 |
| Urinary bladder wall | 7.17E−02 | 2.63E−02 | 2.87E−03 | 1.05E−03 |
| Uterus | 1.28E−02 | 1.01E−03 | 1.10E−04 | 8.73E−06 |
| Total body | 9.39E−03 | 7.64E−04 | – | – |
| ED (mSv/MBq) | 1.43E−02 | 2.60E−04 | ||
| ED (mSv/MBq) ICRP 60 | 1.52E−02 | 5.0E−04 | ||
ODs calculated for the adult male model (73.7 kg, implemented in OLINDA) based on piglet biodistribution and organ geometry data that were scaled to human circumstances
OD organ dose, ED effective dose (ICRP 103), SD standard deviation mean over three animals